CD Formulation is dedicated to the creation of innovative exosome carriers, offering advanced platforms to facilitate efficient nucleic acid delivery. Utilizing cutting-edge technology and customized solutions, projects are tailored to precisely meet client needs, establishing a solid foundation for subsequent research and applications.
Exosomes, tiny vesicles released by cells, range from 30-150 nm in size and are present in body fluids like blood and saliva. They serve as natural carriers, preserving the bioactivity of their contents, and are known for their minimal immune response and high safety profile. Through genetic and chemical modifications, their targeting capabilities can be further enhanced. Exosomes circulate through all body compartments and hold significant potential for delivering non-hepatic-targeting nucleic acids.
Fig.1 General representation of the exosome structure. (Jan A T, et al., 2021)
CD Formulation specializes in developing exosome carriers to optimize nucleic acid delivery systems. By improving exosome extraction and purification techniques, this service aims to enhance intracellular transport efficiency of nucleic acids. This approach combines advanced biotechnology with tailored strategies, striving for greater stability and biocompatibility in carrier design, providing robust support for relevant research.
To enhance exosome yield and quality, various isolation techniques have been refined to ensure consistency with exosome reagents. Assessing the purity of exosome samples is crucial before application in clinical contexts, as contaminants might lead to unintended effects. Current isolation methods include differential/ultracentrifugation, filtration, size-exclusion chromatography, immunoaffinity capture, and polymer precipitation.
After isolation, exosomes undergo a series of characterizations to confirm their identity. The characterization process usually involves analyzing physical features such as size distribution and concentration using techniques like Dynamic Light Scattering (DLS) and Nanoparticle Tracking Analysis (NTA). Additionally, morphological observation via TEM and SEM further verifies the typical vesicular structure of exosomes.
Fig.2 Flow chart of exosome carrier development. (CD Formulation)
Exosomes are extracted from suitable biological samples using techniques like centrifugation and ultrafiltration for initial separation.
Further purification is done via gradient centrifugation or affinity chromatography to enhance exosome purity and quality.
Target nucleic acids (e.g., mRNA, miRNA) are combined with purified exosomes, optimizing loading conditions to improve delivery efficiency.
Prepared exosome carriers undergo characterization, including size, surface markers, and nucleic acid content, to ensure compliance with research requirements.
Platforms | Descriptions |
---|---|
Exosome Platform | Our platform is designed to address the delivery requirements of various nucleic acid drugs, including ASOs, mRNA, siRNA, and miRNA. |
DLS Platform | Used to determine the volume of exosomes. If the sample contains homogeneous exosomes, this method provides accurate size information. |
SPR Platform | It detects various exosomes and quantifies multiple exosome proteins through microfluidic-based SPR chips. |
Technology: Exosome development through drug delivery system platforms
Journal: Frontiers in Bioengineering and Biotechnology
IF: 4.3
Published: 2020
Results:
Exosomes, a form of biological nanoparticles, are advancing rapidly in drug delivery and emerging diagnostics. They exhibit notable stability, efficient cargo transport, and safe cycling, offering potential in modulating cellular communication by delivering various payloads to target sites. Despite demonstrated potential, specific methods for loading and modifying exosomes for improved targeting are still under exploration, and their clinical uses are currently limited. This review highlights both natural and engineered exosomes carrying specific molecules, focusing on strategies to target distinct cell types.
Fig.3 Methods of loading different cargos to specific tissues through engineered exosomes. (Xu M, et al., 2020)
CD Formulation boasts strong technical service capabilities and a professional marketing and after-sales service team. In the future, we will continue adhering to the spirit of endless progress and advancement, keeping pace with life sciences industry trends, providing more outstanding products and quality services to customers. If you are interested in our services and products, please feel free to contact us.
References